# Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid

> **NCT01896895** · PHASE3 · COMPLETED · sponsor: **Merz Pharmaceuticals GmbH** · enrollment: 61 (actual)

## Conditions studied

- Bilateral Blepharospasm (BEB)

## Interventions

- **DRUG:** IncobulinumtoxinA (Xeomin), 25 Units
- **DRUG:** IncobotulinumtoxinA (Xeomin), 12.5 Units
- **DRUG:** Placebo
- **DRUG:** IncobotulinumtoxinA (Xeomin), 35 Units

## Key facts

- **NCT ID:** NCT01896895
- **Lead sponsor:** Merz Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2016-04
- **Final completion:** 2016-11
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2018-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01896895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01896895, "Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01896895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*